Tag:

hostile takeover

Latest Headlines

Latest Headlines

HGS sets deadline for bids: Come and get it!

As if ringing a dinner bell and saying "Come and get it!" Human Genome Sciences ($HGSI) has set a July 16 deadline for someone to come in and save it from the hostile takeover from its long-time partner GlaxoSmithKline ($GSK).

GSK extends $2.6 billion bid for Human Genome Sciences

GlaxoSmithKline ($GSK) said it would and now it has. It extended its $2.6 billion hostile bid for shares of its partner Human Genome Sciences ($HGSI) by three weeks.

Bids value Amylin at up to $4.7B, Bloomberg reports

The latest on Amylin Pharmaceuticals' sales process: Four first-round bids. Four Big Pharma suitors. Offers ranging from $25 to $29 per share, valuing the company at up to $4.7 billion.

Judge blocks run at Human Genome's 'poison pill' defense

Human Genome Sciences ($HGSI) won a court battle in its hostile takeover fight with partner GlaxoSmithKline ($GSK), but faces an ever-expanding and ugly war.

Reuters: Glaxo aims to replace entire HGS board

Citing sources, Reuters says GSK has started scouting for candidates, and it could issue a solicitation to shareholders within a few weeks. The company would also extend its tender offer of $13 per share.

HGS puts 'poison pill' in its arsenal against GSK

Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.

Glaxo goes hostile on HGS with $2.6B bid

Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.

Roche's $5.7B Illumina bid risks standing alone

In the wake of Roche's ($RHHBY) $5.7 billion hostile takeover bid for gene sequencing company Illumina ($ILMN), the jury is still out as to what it means for the industry at large. On the one hand,

Valeant offers a stick, a carrot and a May 12 deadline to Cephalon investors

The CEO of Canada's Valeant Pharmaceuticals has marshaled all of his arguments in favor of a hostile takeover of Cephalon ($CEPH) in a letter designed to woo shareholders, offering to bump the pharma

Valeant may sweeten Cephalon bid

Valeant says it just might be willing to up its bid for Cephalon--once it gets its hands on the books for its due diligence work. Cephalon has been fending off Valeant's hostile acquisition effort,